Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its ...

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded copies of its weight-loss and diabetes drugs, and the CEO said he is alarmed by ...

While Ozempic has been shown to lead to weight loss as a side effect, it's not without risks. According to the Cleveland ...

Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed.

Feb. 22, 2024 When the semaglutide medication Wegovy first hit the market in 2021, it became the first weight-loss drug to ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ acquisition of contract drug ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...